Advertisement

Topics

Peripheral Artery Occlusive Disease (PAOD) - Pipeline Review, H1 2015

01:13 EDT 15 Apr 2015 | BioPortfolio Reports

Recently added to the BioPortfolio report store, Peripheral Artery Occlusive Disease (PAOD) - Pipeline Review, H1 2015 is a new report from Global Markets Direct published on 2015-03-10. This 182-page report is available in PDF from $2000.

Peripheral Artery Occlusive Disease (PAOD) - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Peripheral Artery Occlusive Disease (PAOD) - Pipeline Review, H1 2015’, provides an overview of the Peripheral Artery Occlusive Disease (PAOD)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Peripheral Artery Occlusive Disease (PAOD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peripheral Artery Occlusive Disease (PAOD) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Peripheral Artery Occlusive Disease (PAOD)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Peripheral Artery Occlusive Disease (PAOD) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Peripheral Artery Occlusive Disease (PAOD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Peripheral Artery Occlusive Disease (PAOD) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Table of Contents
Table of Contents 2
List of Tables 8
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Peripheral Artery Occlusive Disease (PAOD) Overview 11
Therapeutics Development 12
Pipeline Products for Peripheral Artery Occlusive Disease (PAOD) - Overview 12
Pipeline Products for Peripheral Artery Occlusive Disease (PAOD) - Comparative Analysis 13
Peripheral Artery Occlusive Disease (PAOD) - Therapeutics under Development by Companies 14
Peripheral Artery Occlusive Disease (PAOD) - Pipeline Products Glance 18
Late Stage Products 18
Clinical Stage Products 19
Early Stage Products 20
Unknown Stage Products 21
Peripheral Artery Occlusive Disease (PAOD) - Products under Development by Companies 22
Peripheral Artery Occlusive Disease (PAOD) - Companies Involved in Therapeutics Development 26
Annexin Pharmaceuticals AB 26
Apceth GmbH & Co. KG 27
AstraZeneca PLC 28
Athersys, Inc. 29
Bayer AG 30
Betagenon AB 31
Cardiolynx AG 32
CardioVascular BioTherapeutics, Inc. 33
Celgene Corporation 34
Cytokinetics, Inc. 35
Diffusion Pharmaceuticals LLC 36
DNAVEC Corporation 37
Genovate Biotechnology Co., LTD. 38
Grifols, S.A. 39
Human Stem Cells Institute 40
Kowa Company, Ltd. 41
Lacer, S.A. 42
Ligand Pharmaceuticals, Inc. 43
LTT Bio-Pharma Co., Ltd. 44
miRagen Therapeutics, Inc. 45
Multi Gene Vascular Systems Ltd 46
Nuo Therapeutics, Inc. 47
Pluristem Therapeutics Inc. 48
Proteon Therapeutics, Inc. 49
Recardio GmbH 50
RegenoCELL Therapeutics, Inc. 51
Rigel Pharmaceuticals, Inc. 52
Sagene Pharmaceuticals, Inc. 53
Stemedica Cell Technologies, Inc. 54
Taisho Toyama Pharmaceutical Co., Ltd. 55
Theravasc, Inc. 56
vasopharm GmbH 57
ViroMed Co., Ltd. 58
Peripheral Artery Occlusive Disease (PAOD) - Therapeutics Assessment 59
Assessment by Monotherapy Products 59
Assessment by Combination Products 60
Assessment by Target 61
Assessment by Mechanism of Action 63
Assessment by Route of Administration 65
Assessment by Molecule Type 67
Drug Profiles 69
(cilostazol + organic nitrate) ER - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
AEM-28 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
ALD-301 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
Alecmestencel-T - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
alprostadil - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
Annexin A-5 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
AP-01 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
cilostazol CR - Drug Profile 78
Product Description 78
Mechanism of…

For more information open Peripheral Artery Occlusive Disease (PAOD) - Pipeline Review, H1 2015.

SKU: GMDHC6257IDB

Original Article: Peripheral Artery Occlusive Disease (PAOD) - Pipeline Review, H1 2015

NEXT ARTICLE

More From BioPortfolio on "Peripheral Artery Occlusive Disease (PAOD) - Pipeline Review, H1 2015"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...